These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8642359)
21. Protective effect of selegiline in the early and late phases of Parkinson's disease. Csanda E; Tárczy M Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208 [No Abstract] [Full Text] [Related]
22. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Ondo WG; Sethi KD; Kricorian G Clin Neuropharmacol; 2007; 30(5):295-300. PubMed ID: 17909308 [TBL] [Abstract][Full Text] [Related]
23. [Deprenyl as a co-adjuvant in the treatment of Parkinson disease]. Ferrari E; Cacudi N; de Mari M; Iliceto G; Lamberti P Acta Neurol (Napoli); 1986 Aug; 8(4):455-61. PubMed ID: 3096087 [No Abstract] [Full Text] [Related]
24. [The evolution of use of anti-Parkinson drugs in Spain]. Montané E; Vallano Ferraz A; Castel JM Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509 [TBL] [Abstract][Full Text] [Related]
25. Selegiline slows the progression of the symptoms of Parkinson disease. Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R; Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603 [TBL] [Abstract][Full Text] [Related]
26. Selegiline and mortality in Parkinson's disease. Olanow CW; Fahn S; Langston JW; Godbold J Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088 [No Abstract] [Full Text] [Related]
27. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848 [TBL] [Abstract][Full Text] [Related]
28. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Klivényi P; Vécsei L Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774 [TBL] [Abstract][Full Text] [Related]
29. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
30. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. Papapetropoulos S; Argyriou AA Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591 [No Abstract] [Full Text] [Related]
32. Early combination with deprenyl: a retrospective analysis. Fornadi F; Ulm G Adv Neurol; 1990; 53():437-40. PubMed ID: 2122650 [No Abstract] [Full Text] [Related]
33. [Slowing the progression of Parkinson syndrome by early administration of deprenyl]. Baas H; Fischer PA Nervenarzt; 1990 Feb; 61(2):127-9. PubMed ID: 2108395 [No Abstract] [Full Text] [Related]